BioNTech expects to start supplying two omicron-adapted vaccines as soon as October, which will help stimulate demand in the fourth quarter, the German biotech company said as it reaffirmed its vaccine revenue forecast for the year on Monday.

Pending regulatory approval, both vaccines will be supplied in time for booster campaigns next fall, the company said.

Second-quarter revenue and net profit fell about 40% compared to the same period a year earlier, to €3.2 billion ($3.26 billion) and €1.672 billion, respectively.

It also reaffirmed its vaccine revenue forecasts for 2022, of between 13,000 and 17,000 million euros, compared to 19,000 million last year.

“With our strong results to date, we believe we are on track to meet our previous financial guidance for the current financial year,” said Jens Holstein, CFO of BioNTech.

“With our initiatives around variant-tailored COVID-19 vaccine candidates, we expect increased demand in our key markets in Q4 2022, subject to regulatory approval.”

Categorized in: